Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

被引：10
|
作者：
Crews, Kristine R. [1 ]
Caudle, Kelly E. [1 ]
Dunnenberger, Henry M. [2 ]
Sadhasivam, Senthilkumar [3 ,4 ]
Skaar, Todd C. [5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] NorthShore Univ Hlth Syst, Ctr Mol Med, Evanston, IL USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA
[5] Indiana Univ Sch Med, Div Clin Pharmacol, Dept Med, Indianapolis, IN 46202 USA
来源：
CLINICAL CHEMISTRY | 2015年 / 61卷 / 05期
关键词：
PHARMACOGENETICS; IMPLEMENTATION;
D O I：
10.1373/clinchem.2014.237412
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [1] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    Goetz, Matthew P.
    Sangkuhl, Katrin
    Guchelaar, Henk-Jan
    Schwab, Matthias
    Province, Michael
    Whirl-Carrillo, Michelle
    Symmans, W. Fraser
    McLeod, Howard L.
    Ratain, Mark J.
    Zembutsu, Hitoshi
    Gaedigk, Andrea
    van Schaik, Ron H.
    Ingle, James N.
    Caudle, Kelly E.
    Klein, Teri E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 770 - 777
  • [2] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
    Bell, G. C.
    Caudle, K. E.
    Whirl-Carrillo, M.
    Gordon, R. J.
    Hikino, K.
    Prows, C. A.
    Gaedigk, A.
    Agundez, J. A. G.
    Sadhasivam, S.
    Klein, T. E.
    Schwab, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 213 - 218
  • [3] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
    Crews, K. R.
    Gaedigk, A.
    Dunnenberger, H. M.
    Klein, T. E.
    Shen, D. D.
    Callaghan, J. T.
    Kharasch, E. D.
    Skaar, T. C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
  • [4] CLINICAL PRACTICE GUIDELINE: CYP2D6 GENOTYPING FOR SAFE AND EFFICACIOUS CODEINE THERAPY
    Madadi, Parvaz
    Amstutz, Ursula
    Rieder, Michael
    Ito, Shinya
    Fung, Vincent
    Hwang, Soomi
    Turgeon, Jacques
    Michaud, Veronique
    Koren, Gideon
    Carleton, Bruce C.
    [J]. JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2013, 20 (03): : E369 - E396
  • [5] Ethical Considerations in CYP2D6 Genotype Testing for Codeine-Prescribed Breastfeeding Mothers
    Kurtz, M.
    Golde, P. Black
    Berlinger, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) : 760 - 762
  • [6] CYP2D6 genotyping and codeine
    De Leon, Jose
    [J]. PEDIATRIC ANESTHESIA, 2008, 18 (03) : 274 - 275
  • [7] CYP2D6 genotyping and codeine - Reply
    Voronov, Polina
    [J]. PEDIATRIC ANESTHESIA, 2008, 18 (03) : 275 - 276
  • [8] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    [J]. MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [9] Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype
    Stamer, U. M.
    Stueber, F.
    [J]. ANAESTHESIA, 2007, 62 (12) : 1294 - 1295
  • [10] CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies
    Goetz, M. P.
    Ingle, J. N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 141 - 144
12345